Cerebrospinal fluid amyloid β1-42 levels in the mild cognitive impairment stage of Alzheimer's disease

Masahiro Maruyama, Hiroyuki Arai, Mitsunori Sugita, Haruko Tanji, Makoto Higuchi, Nobuyuki Okamura, Toshifumi Matsui, Susumu Higuchi, Sachio Matsushita, Hiroshi Yoshida, Hidetada Sasaki

Research output: Contribution to journalArticlepeer-review

88 Citations (Scopus)

Abstract

Cerebrospinal fluid (CSF) levels of amyloid β-protein ending at amino acid position 42 (CSF-A β1-42) and CSF-tau levels were quantified by sandwich ELISAs in 19 patients with mild cognitive impairment (MCI) who eventually developed Alzheimer's disease (AD) on follow-up as well as in 15 age-matched normal controls and 54 AD patients at diverse stages of the disease. In the present study, the annual conversion rate was approximately 15%. The CSF-A β1-42 levels did not differ significantly between the normal control group and the MCI group, however, these values declined significantly once AD became clinically overt. In contrast to CSF-A β1-42, CSF-tau levels were significantly increased in the MCI stage, and these values continued to be elevated thereafter, indicating that increased levels of CSF-tau may help in detecting MCI subjects who are predicted to develop AD. We propose that CSF-tau and CSF-A β1-42 must be used as two distinct biomarkers that should be applied appropriately in clinical settings.

Original languageEnglish
Pages (from-to)433-436
Number of pages4
JournalExperimental Neurology
Volume172
Issue number2
DOIs
Publication statusPublished - 2001

Keywords

  • Alzheimer's disease
  • Amyloid β-protein
  • Biomarker
  • Cerebrospinal fluid
  • Mild cognitive impairment
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Fingerprint Dive into the research topics of 'Cerebrospinal fluid amyloid β<sub>1-42</sub> levels in the mild cognitive impairment stage of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this